Ligand Pharmaceuticals Inc. (LGND)
| Market Cap | 1.18B |
| Revenue (ttm) | 241.67M |
| Net Income (ttm) | -21.29M |
| Shares Out | 16.89M |
| EPS (ttm) | 1.47 |
| PE Ratio | 49.43 |
| Forward PE | 35.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,745 |
| Open | 69.12 |
| Previous Close | 69.99 |
| Day's Range | 68.44 - 73.09 |
| 52-Week Range | 45.27 - 102.83 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 128.35 (+76.6%) |
| Earnings Date | Nov 7, 2022 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight agai... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 128.35, which is an increase of 76.64% from the latest price.
News
Ligand to Hold Investor and Analyst Day on December 13
SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 ...
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
EMERYVILLE, Calif.--( BUSINESS WIRE )--OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb wa...
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates
Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand Reports Third Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand Reports Third Quarter 2022 Financial Results
Ligand Announces Completion of OmniAb Spin-Off
SAN DIEGO--(BUSINESS WIRE)--Ligand Announces Completion of OmniAb Spin-Off
OmniAb Announces Completion of Spin-Off and Business Combination
EMERYVILLE, Calif.
Ligand Distribution of OmniAb Complete and Business Combination Closed
SAN DIEGO--(BUSINESS WIRE)--Ligand Distribution of OmniAb Complete and Business Combination Closed
Ligand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand to Report Third Quarter Financial Results on November 7
SAN DIEGO--(BUSINESS WIRE)--Ligand to Report Third Quarter Financial Results on November 7
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Pa...
SAN DIEGO--(BUSINESS WIRE)--Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab)
OmniAb Business Combination Approved by APAC Shareholders
SAN DIEGO--(BUSINESS WIRE)--OmniAb Business Combination Approved by APAC Shareholders
LGND vs. RGEN: Which Stock Is the Better Value Option?
LGND vs. RGEN: Which Stock Is the Better Value Option?
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Trea...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the Eur...
Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates
Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand Reports Second Quarter 2022 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Reports Second Quarter 2022 Financial Results
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Ligand to Report Second Quarter Financial Results on August 8
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Mon...
Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses
Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
Spot the Red Flags & Sell These 5 Toxic Stocks Right Away
Detoxify your holdings by steering clear of these five stocks, Alarm.com (ALRM), Ligand (LGND), Radius Global (RADI), ADT Inc. (ADT) and Madison Square (MSGE).